- The issue of BRCA mutations on clinical point of view2016 | Third Faculty of Medicine
- Overview on population screening for carriers with germline BRCA mutation in China2022 | Faculty of Medicine in Pilsen
- Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.2011 | First Faculty of Medicine
- BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction2023 | First Faculty of Medicine, Third Faculty of Medicine
- Hereditary risk of ovarian cancer and its prophylactic measures2018 | Faculty of Medicine in Pilsen
- Ovarian cancer - hereditary disposition2018 | Faculty of Medicine in Pilsen
- Brest cancer2018 | Third Faculty of Medicine
- Olaparib as a maintenance therapy in newly diagnosed patients with ovarian cancer - SOLO1 study results2022 | Third Faculty of Medicine
- Can be considered the primary fallopian tube cancer an enigma at the beginning of the third millenium?2013 | Faculty of Medicine in Hradec Králové
- Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management2016 | First Faculty of Medicine
- Tubal ligation and the risk of ovarian cancer: review and meta-analysis2011 | First Faculty of Medicine
- Epigenome-based cancer risk prediction: rationale, opportunities and challenges2018 | First Faculty of Medicine
- Prophylactic mastectomy in BRCA carriers from point of view of plastic surgery2018 | Faculty of Medicine in Pilsen
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerPublication without faculty affiliation
- Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer2022 | Faculty of Medicine in Pilsen
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial2015 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum - sensitive ovarian cancer : a randomised phase 2trial2015 | Publication without faculty affiliation
- Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial2023 | First Faculty of Medicine
- Options and consequences of genetic testing in patients with high risk of breast and ovarian cancer due to BRCA1 and BRCA2 mutations2015 | Faculty of Medicine in Pilsen
- Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands2017 | Faculty of Medicine in Pilsen
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples2022 | First Faculty of Medicine
- Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients2023 | First Faculty of Medicine
- Are population level familial risks and germline genetics meeting each other?2023 | Faculty of Medicine in Pilsen
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)2022 | Third Faculty of Medicine